Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Global HealthBOM:543654 -0.04%96 Altman Z-Score is 13.91 as of Aug. 26, 2026, which is 6% above its 10-year median of 13.13. GuruFocus rates BOM:543654 with a GF Score™ of 96/100 and a GF Value™ of ₹1,562.98 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 656 Healthcare Providers & Services companies, Global Health ranks better than 93.75% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 13.92 is strong.
Global Health has a Altman Z-Score of 13.91, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Global Health's Altman Z-Score or its related term are showing as below:
BOM:543654'
s Altman Z-Score Range Over the Past 10 Years
Min: 6.61 Med: 13.13 Max: 17.36
Current: 13.92
During the past 7 years, Global Health's highest Altman Z-Score was 17.36. The lowest was 6.61. And the median was 13.13.
Global Health (BOM:543654) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Global Health Altman Z-Score Related Terms
Global Health Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Global Health's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543654 vs HCA, THC, DVA: Altman Z-Score Comparison
For the Medical Care Facilities subindustry, Global Health's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Global Health Altman Z-Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Global Health's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Global Health's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Global Health's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.1774
+
1.4
*
0.4734
+
3.3
*
0.1375
+
0.6
*
19.6524
+
1.0
*
0.7931
=
13.91
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Global Health (BOM:543654) has a Altman Z-Score of 13.91 as of Aug. 26, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Global Health and its competitors. This is near median its historical median of 13.13. Over the past decade, Global Health's Altman Z-Score has ranged from 6.61 to 17.36. According to the industry distribution chart, Global Health ranks #41 out of 656 companies in the Healthcare Providers & Services industry, placing it in the top 6.2%.
Is Global Health's Altman Z-Score too high?
Global Health's current Altman Z-Score of 13.91 is near median its 10-year median of 13.13. Over the past 10 years, this metric has ranged from a low of 6.61 to a high of 17.36. The Healthcare Providers & Services industry median Altman Z-Score is 2.41. Global Health's value of 13.91 is 477.2% above this industry median. Based on the distribution chart, Global Health ranks #41 out of 656 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Global Health has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Global Health's Altman Z-Score compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Global Health ranks #41 out of 656 companies for Altman Z-Score. This places Global Health in the top 6% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.41. Global Health's value of 13.91 is 477.2% above this benchmark. Historically, Global Health's own Altman Z-Score has ranged from 6.61 to 17.36 over the past decade. While the company's 10-year median is 13.13 vs. the industry median of 2.41, Global Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Healthcare Providers & Services company?
The median Altman Z-Score among Healthcare Providers & Services companies is 2.41, based on 656 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Global Health's current Altman Z-Score of 13.91 is 477.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Global Health and its competitors. For the Healthcare Providers & Services industry, the median Altman Z-Score is 2.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Global Health's current Altman Z-Score is 13.91, which is near median its own 10-year median of 13.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Global Health stock overvalued right now?
Based on GuruFocus' analysis, Global Health (BOM:543654) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,562.98, compared to a current price of ₹1,404.70 — trading 10.1% below its estimated fair value. The current Altman Z-Score is 13.91, which is near median its 10-year median of 13.13 and 477.2% above the Healthcare Providers & Services industry median of 2.41. Global Health's overall GF Score™ is 96/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Global Health (BOM:543654), the current Altman Z-Score is 13.91 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Global Health (BOM:543654) Overvalued in 2026?
Based on GuruFocus' analysis, Global Health stock appears to be undervalued.
The current stock price of ₹1,404.70 is trading 10.1% below its estimated GF Value™ of ₹1,562.98.
GuruFocus considers Global Health to be Modestly Undervalued.
Key valuation signals for BOM:543654:
Altman Z-Score: 13.91 (near median its 10-year median of 13.13)
GF Value™: ₹1,562.98 vs. price of ₹1,404.70 (10.1% below fair value)
Industry Position: 477.2% above the Healthcare Providers & Services median (#41 of 656)
No single metric tells the full story. See the BOM:543654 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Global Health Ltd operates as a private multi-specialty tertiary care provider operating in the North and East regions of India, with key specialties of cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology. Under the Medanta brand, it has a network of hospitals in operation (Gurugram, Indore, Ranchi, and Lucknow), a hospital that is under construction with an operational outpatient facility (Patna), and a hospital (Noida) planned for development. The Group operates Healthcare services as a single business segment in India, constituting a single geographical segment.
96GF Score
Get the complete analysis for BOM:543654
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543654 has been successfully added to your 
